



IN - HOUSE PROGRAMS

CURRENT STAGE OF DEVELOPMENT

Program/Molecule Name	Investigational Indication	Pre-Clinical	Phase 1/2a	Registration Trial	Initial Indication
OROTECAN® (oral irinotecan HCl)	Pediatric & Adult Malignancies	[Blue bar]			Ewing Sarcoma
EO-3001 - ARID1a Targeted Therapy	Ovarian Clear Cell Cancer & Solid Tumors	[Blue bar]			OCCC
EO-4426 (tezacitabine)	Solid Tumors & Hematologic Malignancies	[Blue bar]			Solid Tumors

PARTNERED PROGRAMS

CURRENT STAGE OF DEVELOPMENT

Program/Molecule Name	Investigational Indication	Pre-Clinical	Phase 1/2a	Registration Trial	Initial Indication	Development Partner
EO-1001 Pan-ErbB inhibitor	Solid Tumors	[Blue bar]			PARP-resistant cancers	
DNA-Damage Response Inhibitors	Solid Tumors	[Blue bar]			TBD	

* ErbB-1(EGFR) positive cancer, ErbB-2(HER2) positive cancer, ERbB-4 (HER4) positive cancer